Topics
News
CME/CE
Editorial Advisory Board
Partnerships
Efalizumab Lifts Quality of Life in Just Two Weeks
Winston-Salem, N.C. - After subcutaneous treatment with efalizumab(Raptiva), patients who achieved 50 to 75 percent improvement in PsoriasisArea and Severity Index (PASI) score reported improvement in quality oflife.
Related Videos
Related Content
